Le Lézard
Classified in: Health
Subject: SVY

The Global Veterinary Clostridium Vaccine Market is expected to grow by USD 158.58 mn during 2020-2024, progressing at a CAGR of 5% during the forecast period


NEW YORK, March 30, 2020 /PRNewswire/ --

Global Veterinary Clostridium Vaccine Market 2020-2024
The analyst has been monitoring the global veterinary clostridium vaccine market and it is poised to grow by USD 158.58 mn during 2020-2024, progressing at a CAGR of 5% during the forecast period. Our reports on global veterinary clostridium vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Read the full report: https://www.reportlinker.com/p05015477/?utm_source=PRN 

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by dependency on livestock products. In addition, inorganic growth strategies is anticipated to boost the growth of the global veterinary clostridium vaccine market as well. 

Market Segmentation
The global veterinary clostridium vaccine market is segmented as below:
End-User:
? Swine
? Bovine
? Poultry
? Others 

Geographic Segmentation:
? APAC
? Europe
? MEA
? North America
? South America 

Key Trends for global veterinary clostridium vaccine market growth
This study identifies inorganic growth strategies as the prime reasons driving the global veterinary clostridium vaccine market growth during the next few years. 

Prominent vendors in global veterinary clostridium vaccine market 2020-2024

We provide a detailed analysis of around 25 vendors operating in the global veterinary clostridium vaccine market 2020-2024, including some of the vendors such as Bioveta AS, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Covetrus Inc., Elanco, Animal Health Inc., LABORATORIOS HIPRA SA, Merck & Co. Inc., Vetoquinol SA, Virbac Group and Zoetis Inc. .
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Read the full report: https://www.reportlinker.com/p05015477/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...

at 08:00
Human Immunology Biosciences (HI-Biotm), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that two abstracts have been accepted for oral presentation at the...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: